Bill Gates' Investment Firm Takes Stake in Schrödinger
May 03, 2010
Bill Gates' Investment Firm Takes Stake in Schrödinger
Schrödinger said that the investment will allow it to pursue several research and development projects "with the aim of making considerable improvements in the state of the art in computer-aided drug design."
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Schrodinger to Add AVS Interactive Graphics to Cheminformatics Software
March 9, 2012 / BioInform - UChicago Awarded $1.5M Grant to Develop Computational Framework for Studying Biomolecular Activity
February 3, 2012 / BioInform - Schrödinger Acquires PyMOL, Will Keep It Open Source to 'Honor' DeLano's Memory
January 22, 2010 / BioInform